{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:00:18Z","timestamp":1789963218809,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T00:00:00Z","timestamp":1392768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10549-014-2867-0","type":"journal-article","created":{"date-parts":[[2014,2,18]],"date-time":"2014-02-18T07:46:22Z","timestamp":1392709582000},"page":"249-261","source":"Crossref","is-referenced-by-count":41,"title":["Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer"],"prefix":"10.1007","volume":"144","author":[{"given":"Mitsuchika","family":"Hosoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiroh","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako C.","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Takakuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,19]]},"reference":[{"key":"2867_CR1","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474\u20131481","journal-title":"J Clin Oncol"},{"key":"2867_CR2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2325\/jbcs.13.74","volume":"13","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H (2006) Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74\u201383","journal-title":"Breast Cancer"},{"key":"2867_CR3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","volume":"26","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059\u20131065","journal-title":"J Clin Oncol"},{"key":"2867_CR4","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.2010.30.3677","volume":"29","author":"JM Bartlett","year":"2011","unstructured":"Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C et al (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531\u20131538","journal-title":"J Clin Oncol"},{"key":"2867_CR5","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784\u20132795","journal-title":"J Clin Oncol"},{"key":"2867_CR6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2010-0302","volume":"16","author":"JP Thakkar","year":"2011","unstructured":"Thakkar JP, Mehta DG (2011) A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16:276\u2013285","journal-title":"Oncologist"},{"key":"2867_CR7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736\u20131747","journal-title":"Ann Oncol"},{"key":"2867_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mds430","volume":"24","author":"G Cancello","year":"2013","unstructured":"Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A et al (2013) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24:661\u2013668","journal-title":"Ann Oncol"},{"key":"2867_CR9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","volume":"31","author":"A Prat","year":"2013","unstructured":"Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31:203\u2013209","journal-title":"J Clin Oncol"},{"key":"2867_CR10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771\u2013784","journal-title":"Lancet"},{"key":"2867_CR11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1111\/j.1349-7006.2009.01274.x","volume":"100","author":"H Yamashita","year":"2009","unstructured":"Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y et al (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100:2028\u20132033","journal-title":"Cancer Sci"},{"key":"2867_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-013-2426-0","volume":"138","author":"BP Haynes","year":"2013","unstructured":"Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A\u2019Hern R, Smith IE, Dowsett M (2013) Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 138:157\u2013165","journal-title":"Breast Cancer Res Treat"},{"key":"2867_CR13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1200\/JCO.2009.23.9616","volume":"28","author":"AK Dunbier","year":"2010","unstructured":"Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A\u2019Hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A et al (2010) Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 28:1161\u20131167","journal-title":"J Clin Oncol"},{"key":"2867_CR14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/annonc\/mdq596","volume":"22","author":"H Yamashita","year":"2011","unstructured":"Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Endo Y, Fujii Y, Kobayashi S (2011) Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol 22:1318\u20131325","journal-title":"Ann Oncol"},{"key":"2867_CR15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2013.49.4062","volume":"31","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Yamamoto-Ibusuki M, Iwase H (2013) Menopausal status should be taken into consideration for patients with luminal a breast cancer in terms of the effect of differential biology on prognosis. J Clin Oncol 31:2516","journal-title":"J Clin Oncol"},{"key":"2867_CR16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsbmb.2007.05.024","volume":"106","author":"H Anderson","year":"2007","unstructured":"Anderson H, Bulun S, Smith I, Dowsett M (2007) Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106:49\u201354","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2867_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","volume":"89","author":"RM Elledge","year":"2000","unstructured":"Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK (2000) Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 89:111\u2013117","journal-title":"Int J Cancer"},{"key":"2867_CR18","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2001.19.18.3808","volume":"19","author":"MJ Ellis","year":"2001","unstructured":"Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and\/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808\u20133816","journal-title":"J Clin Oncol"},{"key":"2867_CR19","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr1536","volume":"8","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8:R48","journal-title":"Breast Cancer Res"},{"key":"2867_CR20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/bjc.2011.228","volume":"105","author":"EK Millar","year":"2011","unstructured":"Millar EK, Graham PH, McNeil CM, Browne L, O\u2019Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C et al (2011) Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 105:272\u2013280","journal-title":"Br J Cancer"},{"key":"2867_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6890-13-5","volume":"13","author":"T Kobayashi","year":"2013","unstructured":"Kobayashi T, Iwaya K, Moriya T, Yamasaki T, Tsuda H, Yamamoto J, Matsubara O (2013) A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol 13:5","journal-title":"BMC Clin Pathol"},{"key":"2867_CR22","doi-asserted-by":"crossref","unstructured":"Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H (2013) Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. doi: 10.1007\/s12282-013-0474-2","DOI":"10.1007\/s12282-013-0474-2"},{"key":"2867_CR23","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","volume":"25","author":"G Viale","year":"2007","unstructured":"Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell\u2019Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846\u20133852","journal-title":"J Clin Oncol"},{"key":"2867_CR24","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/j.1349-7006.2011.02047.x","volume":"102","author":"N Yoshimoto","year":"2011","unstructured":"Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H (2011) Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci 102:2065\u20132072","journal-title":"Cancer Sci"},{"key":"2867_CR25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-10-2507","volume":"18","author":"WC Dougall","year":"2012","unstructured":"Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL\/RANK\/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:326\u2013335","journal-title":"Clin Cancer Res"},{"key":"2867_CR26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/465695a","volume":"465","author":"JP Lydon","year":"2010","unstructured":"Lydon JP (2010) Stem cells: cues from steroid hormones. Nature 465:695\u2013696","journal-title":"Nature"},{"key":"2867_CR27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrc3518","volume":"13","author":"C Brisken","year":"2013","unstructured":"Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385\u2013396","journal-title":"Nat Rev Cancer"},{"key":"2867_CR28","doi-asserted-by":"crossref","unstructured":"Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, et al (2013) Progesterone\/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5:182ra55","DOI":"10.1126\/scitranslmed.3005654"},{"key":"2867_CR29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10549-011-1482-6","volume":"131","author":"RJ Mehta","year":"2012","unstructured":"Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S (2012) FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 131:881\u2013890","journal-title":"Breast Cancer Res Treat"},{"key":"2867_CR30","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-07-0122","volume":"13","author":"S Badve","year":"2007","unstructured":"Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H (2007) FOXA1 expression in breast cancer\u2014correlation with luminal subtype A and survival. Clinical Cancer Res 13:4415\u20134421","journal-title":"Clinical Cancer Res"},{"key":"2867_CR31","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ejca.2008.04.020","volume":"44","author":"HO Habashy","year":"2008","unstructured":"Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44:1541\u20131551","journal-title":"Eur J Cancer"},{"key":"2867_CR32","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1245\/s10434-011-2094-4","volume":"19","author":"Y Hisamatsu","year":"2012","unstructured":"Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y (2012) Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol 19:1145\u20131152","journal-title":"Ann Surg Oncol"},{"key":"2867_CR33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/ERC-12-0207","volume":"20","author":"Y Endo","year":"2013","unstructured":"Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H (2013) miR-1290 and its potential targets are associated with characteristics of estrogen receptor alpha-positive breast cancer. Endocr Relat Cancer 20:91\u2013102","journal-title":"Endocr Relat Cancer"},{"key":"2867_CR34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2006.09.048","volume":"127","author":"H Kouros-Mehr","year":"2006","unstructured":"Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:1041\u20131055","journal-title":"Cell"},{"key":"2867_CR35","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370","DOI":"10.1038\/nature11412"},{"key":"2867_CR36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/msb.2011.59","volume":"7","author":"SL Kong","year":"2011","unstructured":"Kong SL, Li G, Loh SL, Sung WK, Liu ET (2011) Cellular reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol 7:526","journal-title":"Mol Syst Biol"},{"key":"2867_CR37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrc3539","volume":"13","author":"EW Lam","year":"2013","unstructured":"Lam EW, Brosens JJ, Gomes AR, Koo CY (2013) Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 13:482\u2013495","journal-title":"Nat Rev Cancer"},{"key":"2867_CR38","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr2249","volume":"11","author":"J Jacquemier","year":"2009","unstructured":"Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D (2009) Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 11:R23","journal-title":"Breast Cancer Res"},{"key":"2867_CR39","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr3145","volume":"14","author":"I Pinhel","year":"2012","unstructured":"Pinhel I, Hills M, Drury S, Salter J, Sumo G, A\u2019Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P et al (2012) ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res 14:R46","journal-title":"Breast Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-2867-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-2867-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T18:33:34Z","timestamp":1565202814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-2867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,19]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-2867-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,19]]}}}